Posted by Michael Wonder on 25 May 2023
Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high
25 May 2023 - Amid concern that HIV prevention pills are not being widely taken by those at highest risk of infection, AIDS activists hope that a trial getting underway in a federal courtroom this week will help explain why the medicine has struggled to see uptake.
The litigation accuses Gilead Sciences of using a range of controversial business tactics that led the US health care system to overspend for HIV medicines.
